In practice
How Qor turns evidence into actionable insights.
A financing window, a competitor readout, and a reason to re-engage a past client. Here's how Qor informed each judgement call.
Management consultancies
Reopening the Client Conversation
Turning a completed engagement into the next revenue opportunity.
The question
When does a past client actually need us again, and how do we know before they've told anyone?
The challenge
A management consultancy partner delivers an eight-week leadership alignment engagement for a large biotech client, helping the C-suite align focus areas around a specific therapeutic space. The project closes, the invoice is paid, and the team moves to the next client. Without an ongoing signal, the partner has no reliable way of knowing when that client's priorities shift again; they're left relying on Google Alerts and occasional check-in calls, often missing the moment entirely.
How Qor helps
Qor continuously monitors the client's competitive landscape after the engagement ends, tracking competitor movements, pipeline shifts, and market positioning changes relevant to the client's stated focus areas. When something material changes, Qor surfaces it directly to the partner, translating the shift into what it means for the client and why it's worth a conversation now, rather than the partner discovering it weeks later, or not at all.
Outcome
- Partner re-engages the client CEO directly, armed with a specific, current reason to talk
- Relationship stays "live" between engagements instead of going cold
- Pipeline visibility extends beyond the current project's end date
- Replaces ad hoc monitoring (Google Alerts, AlphaSense) with continuous, synthesized signal
- A new engagement, scoped, identified with a past client, not a dead lead
Competitive awareness
Financing & Partnering Window
Knowing how the asset is being judged before the raise goes out.
The question
How are we being read now, and what would strengthen our position before financing and partnering conversations?
The challenge
A biotech is preparing for its next financing while assessing partnering options. The team has strong conviction in the science, but the field is moving: competitor programmes have advanced, investor appetite has shifted, and recent transactions may have changed how the asset is judged.
How Qor helps
Qor gives a current view of the company's position. Which comparators matter most, where the asset is genuinely differentiated, where the field is crowding, and which partners are the strongest fit. It flags what recent developments require leadership to do differently across the financing narrative, partner prioritisation and board discussion.
Outcome
- Constantly refreshed understanding of comparators every asset is judged against
- Amended partner prioritisation shortlist ordered by fit and comparable deals actually paid
- Assumptions in the current investor story that recent data no longer supports, flagged before the roadshow
- Updated financing narrative grounded in the landscape as it stands today
- Every claim in investor materials traceable to its source
Competitive awareness
When a Competitor Reads Out
Translating a competitor readout into a company-specific action plan.
The question
Is this readout positive or negative for us, and what does it require us to do differently across clinical design, BD, investor narrative, IP and runway?
The challenge
A drug discovery biotech is running an asset in post-GLP-1 weight maintenance. Eli Lilly reports Phase 3 data for orforglipron. That strengthens the case for post-GLP-1 maintenance as a defined clinical and commercial category, and raises the bar for every asset in the space.
How Qor helps
Qor reads the announcement against the company's own position, and works out which decisions the readout reaches, across clinical design, BD, investor narrative, IP and runway. Leadership sees which decisions are already taken and which are pending, ranked by how much they matter, before choices compound.
Outcome
- Competitor readout traced to its consequences
- Investor and board narrative refreshed before the window closes
- Decisions ranked by status, cost and impact
- IP and clinical decisions caught before they are expensive to change
Proven foundations
Qor is built on BenevolentAI.
For more than a decade, BenevolentAI has developed and applied AI to complex scientific evidence and consequential decisions in life sciences.
Qor brings together that accumulated capability in scientific knowledge, evidence infrastructure, reasoning methods, machine learning, evaluation and domain expertise.
0+ years
Applying AI to life sciences
0+ patents
Across technology, methods and biology
Peer-reviewed research
Across AI, biomedical knowledge and drug discovery
See Qor in action.
Tell us what you are trying to stay on top of, and watch Qor work on it live.
Book a demo